---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-031966"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2024-10-24T23:59:59+00:00"
generated_at: "2026-05-30T10:30:42.912107+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Genprex partners with U Michigan to study REQORSA plus ALK-inhibitors in ALK+ lung cancer

## Summary
- Entered Sponsored Research Agreement with Univ. of Michigan Rogel Cancer Center for TUSC2/REQORSA combo with ALK-inhibitors.
- Collaboration with ALK Positive nonprofit; both share cost of the SRA.
- Preclinical data (AACR Apr 2024): REQORSA induced apoptosis in alectinib-resistant EML4-ALK+ NSCLC lines.
- TUSC2 overexpression via REQORSA decreased cell growth and proliferation through apoptotic pathway activation.

## SEC filing metadata
- accession: 0001437749-24-031966
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2024-10-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774924031966/0001437749-24-031966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774924031966/gnpx20241002_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-031966
- JSON: https://secwatch.observer/filing/0001437749-24-031966.json
- Plain text: https://secwatch.observer/filing/0001437749-24-031966.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.